Effect and safety analysis of Tigecycline adjuvant treatment of multi-drug resistant bacteria infection in ICU patients
JIANG Xiao-ming1 LIU Xue-jing2 SUN Yu
1.Department of Critical Care Medicine, Beijing Mentougou District Hospital, Beijing 123200, China;
2.Intracardiac Coronary Heart Disease Intensive Care Unit, Hongqi Hospital Affiliated to Mudanjiang Medical College, Heilongjiang Province, Mudanjiang 157011, China;
3.Department of Critical Care Medicine, Hongqi Hospital Affiliated to Mudanjiang Medical College, Heilongjiang Province, Mudanjiang 157011, China
Abstract:Objective To investigate the effect and safety of ticacycline adjuvant treatment for multi-drug resistant bacterial infection in intensive care unit (ICU) patients.Methods A total of 60 patients with multidrug-resistant bacteria infection admitted to the ICU of Beijing Mentougou District Hospital from January 2019 to May 2020 were selected as the research subjects.According to stratified random method, they were divided into experimental group (30 cases) and control group (30 cases).The control group was treated with Cefoperazone and Sulbactam, and the experimental group was treated with Tigecycline on the basis of the control group.The recovery time of C-reactive protein (CRP), white blood cells, chest X-ray plain film, lung rales and body temperature were compared between the two groups.The total incidence of adverse reactions, bacterial reinfection rate, bacterial replacement rate and bacterial clearance rate were compared between the two groups.Results CRP, white blood cells, chest X-ray, lung rales and body temperature recovery time in experimental group were all shorter than those in control group, the differences were statistically significant(P<0.05).The total incidence of adverse reactions, the rate of bacterial reinfection and the rate of bacterial replacement in experimental group were lower than those in control group, and the rate of bacterial clearance was higher than that in control group, the differences were statistically significant (P<0.05).Conclusion The combination of Cefoperazone-Sulbactam and Tigecycline can accelerate the recovery of patients with multi-drug resistant bacteria infection and reduce the occurrence of bacterial infection and adverse reactions.